New treatment option for nonfunctional neuroendocrine tumours of the lung, gastrointestinal tract

The efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumours of lung or gastrointestinal origin has been demonstrated by researchers. Progression-free survival of patients was successfully extended by seven months and the risk of progression of the disease fell by 52%. Everolimus was well tolerated and side-effects were consistent with the known profile. (Mehr in: Cancer News — ScienceDaily)